Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR180575 in mild diabetic peripheral neuropathy
NCT00502515Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SSR180575 in diabetic peripheral neuropathy (DPN) (3 arms), sponsored by Sanofi. Primary endpoint: Rate of epidermal nerve fiber regeneration at 24 weeks. Started Jul 2007; status: completed.
02
Drugs
SSR180575
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00502515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502515.